Chemours Company (The) Common Stock (CC)

NEW YORK CITY, NY / ACCESS Newswire / November 13, 2026 / Levi & Korsinsky, LLP highlights the alleged Chemours promise-reality gap at the center of a securities fraud class action pending on behalf of investors who suffered losses after purchasing The Chemours Company (NYSE:CC) securities between February 20, 2026 and August 4, 2026. Check if you might be eligible to recover your investment losses, or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Chemours (CC) To Contact Him Directly To Discuss Their Options

NEW YORK and NEW ORLEANS, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company (“Chemours” or the “Company”) (NYSE: CC), if they purchased or otherwise acquired the Company’s securities between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”).  This action is pending in the United States District Court for the District of Delaware.

NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours " or the "Company") (NYSE: CC) and certain officers.   The class action, filed in the United States District Court for the District of Delaware, and docketed under 26-cv-01299, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Key Dates and Disclosure Events Shareholders Need to Know. The complaint traces how Chemours allegedly reaffirmed its 2026 outlook from February through May while an oversupplied Opteon aftermarket channel was allegedly eroding the demand behind it

Promise vs. Reality: The Chemours Performance Gap. Management cited "very stable volume" in May, but the lawsuit alleges an oversold Opteon aftermarket channel was already eroding 2026 demand.

CC INVESTOR ALERT

NEW ORLEANS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company (“Chemours” or the “Company”) (NYSE: CC), if they purchased or otherwise acquired The Chemours Company securities between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Delaware.

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours " or the "Company") (NYSE: CC) and certain officers.   The class action, filed in the United States District Court for the District of Delaware, and docketed under 26-cv-01299, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

LOS ANGELES, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against The Chemours Company (“Chemours” or “the Company”) (NYSE: CC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Notice to Pension Funds, Asset Managers, and Fiduciaries: The lawsuit alleges Chemours overstated aftermarket demand for its Opteon refrigerants and reaffirmed 2026 guidance that did not account for sales pulled forward by 2025 distributor stocking

Wall Street Reassessment: Analyst Opinion Evolution on CC. UBS, Morgan Stanley, and J.P. Morgan cut Chemours price targets by as much as 37.9% after a 2026 guidance cut that the lawsuit alleges followed months of overstated Opteon aftermarket demand.

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against The Chemours Company (NYSE:CC) and certain of the company’s senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws.

NEW YORK CITY, NY / ACCESS Newswire / October 30, 2026 / Levi & Korsinsky, LLP reminds purchasers of The Chemours Company (NYSE:CC) securities of a pending securities class action. THE CASE: Investors who bought Chemours securities between February 20, 2026 and August 4, 2026 may be entitled to compensation without payment of any out-of-pocket fees. YOUR OPTIONS: Find out if you might qualify for recovery or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

LOS ANGELES, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against The Chemours Company (“Chemours” or “the Company”) (NYSE: CC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

NEW ORLEANS, Oct. 29, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company (“Chemours” or the “Company”) (NYSE: CC), if they purchased or otherwise acquired The Chemours Company securities between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Delaware.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours " or the "Company") (NYSE: CC) and certain officers. The class action, filed in the United States District Court for the District of Delaware, and docketed under 26-cv-01299, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

LOS ANGELES, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against The Chemours Company (“Chemours” or “the Company”) (NYSE: CC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

A federal refrigerant mandate allegedly anchored Chemours' Opteon growth story, but the lawsuit claims the 2025 AIM Act transition left an overstocked aftermarket channel that undercut the Company's 2026 outlook.

Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons or entities who purchased or otherwise acquired The Chemours Company (NYSE: CC) securities between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”). Chemours offers a range of industrial and specialty chemical products for markets including, as relevant here, refrigeration and air conditioning.

Important Notice Regarding Alleged Opteon Aftermarket Demand Misrepresentations. The lawsuit claims that record 2025 refrigerant sales reflected an overfilled distribution channel, which set up a 2026 sales decline for Chemours shareholders.

The Chemours Company ("Chemours" or the "Company") (NYSE: CC) investors who wish to serve as lead plaintiff in a pending securities fraud class action lawsuit must move the Court by December 7, 2026. The suit was filed on behalf of investors who purchased or otherwise acquired the Company's securities from February 20, 2026 through August 4, 2026, inclusive. The Law Offices of Howard G. Smith today highlighted the deadline in the case, Darcy v. The Chemours Company et al., which was filed on October 8, 2026 in the U.S. District Court District of Delaware (Wilmington) (Case No. 1:26-cv-01299).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK CITY, NY / ACCESS Newswire / October 23, 2026 / Levi & Korsinsky, LLP notifies pension funds, asset managers, and other institutional investors in The Chemours Company (NYSE:CC) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between February 20, 2026 and August 4, 2026, before an 18.63% single-session decline in CC shares. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

NEW ORLEANS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company (“Chemours” or the “Company”) (NYSE: CC), if they purchased or otherwise acquired The Chemours Company securities between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Delaware.